Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer

 
• By Jessica Merrill
  
tumor microenvironment
Gilead signed a deal with Compugen for an early novel immuno-oncology asset • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business